<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 10.3</label>
 <caption>
  <p>Drug regimens used for the treatment of MERS and SARS-CoV infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Treatment</th>
    <th>Outcome</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="2">
     <italic>MERS-CoV infection</italic>
    </td>
   </tr>
   <tr>
    <td>
     <p>Ribavirin (oral/IV)</p>
     <p>IFN-ἀ 2b</p>
     <p>Corticosteroids</p>
    </td>
    <td>Late treatment administration. Disease progression delayed and all patients died</td>
   </tr>
   <tr>
    <td>
     <p>Ribavirin (oral/IV)</p>
     <p>PEGylated IFN-ἀ (IV)</p>
     <p>± Corticosteroids</p>
    </td>
    <td>
     <p>Treatment was given 0–8 days after diagnosis</p>
     <p>Significant decreases in hemoglobin and absolute neutrophil count (baseline count lower in treatment group) were also reported</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Ribavirin (oral/IV)</p>
     <p>Lopinavir/ritonavir</p>
     <p>IFN-ἀ-2b</p>
    </td>
    <td>
     <p>No detectable viral RNA in serum after 2 days of therapy</p>
     <p>Ribavirin discontinued due to jaundice, hyperbilirubinemia</p>
     <p>Patients died with septic shock in 2 months</p>
    </td>
   </tr>
   <tr>
    <td colspan="2">
     <italic>SARS-CoV infection</italic>
    </td>
   </tr>
   <tr>
    <td>
     <p>Ribavirin (oral/IV)</p>
     <p>Antibiotics</p>
     <p>± Corticosteroids</p>
     <p>± Immunoglobulin</p>
    </td>
    <td>
     <p>No increased positive outcome with ribavirin compared to controls</p>
     <p>Increased risk of anemia, hypomagnesemia, hypoxia, or bradycardia with ribavirin compared to ribavirin-naive patients</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Ribavirin (oral/IV)</p>
     <p>Lopinavir/ritonavir</p>
     <p>± Corticosteroids</p>
    </td>
    <td>Fatality or acute respiratory distress syndrome (ARDS) was reduced significantly from 28.8% to 2.4%</td>
   </tr>
   <tr>
    <td>
     <p>IFN-alfacon-1</p>
     <p>± Corticosteroids</p>
     <p>± Antibiotics</p>
    </td>
    <td>
     <p>Increased oxygen saturation</p>
     <p>Increased clearance of lung abnormalities</p>
     <p>Slight increase in creatinine kinase concentrations</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Fluoroquinolone (IV)</p>
     <p>Azithromycin (IV)</p>
     <p>IFN-α (IM)</p>
     <p>± Corticosteroids</p>
     <p>± Immunoglobulins</p>
     <p>± Thymic peptides/proteins</p>
    </td>
    <td>No increased positive outcome</td>
   </tr>
   <tr>
    <td>
     <p>Quinolone (IV)</p>
     <p>Azithromycin (IV)</p>
     <p>± IFN-α</p>
     <p>± Corticosteroids</p>
    </td>
    <td>No increased positive outcome</td>
   </tr>
   <tr>
    <td>
     <p>Levofloxacin</p>
     <p>Azithromycin</p>
     <p>± IFN-α</p>
     <p>± Corticosteroids</p>
    </td>
    <td>
     <p>Increased survival</p>
     <p>Increased clearance of lung abnormalities</p>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
